In focus · trending topic

HER2

6 stories · following the connections

Cascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases

By Nasdaq OMXJun 8, 2017, 12:01 PM UTC

Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results

By Nasdaq OMXMar 9, 2017, 9:02 PM UTC

Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results

By Nasdaq OMXMar 9, 2017, 9:02 PM UTC

Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress

By Nasdaq OMXJan 5, 2017, 1:02 PM UTC

Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress

By Nasdaq OMXJan 5, 2017, 1:02 PM UTC

Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress

By Nasdaq OMXJan 5, 2017, 1:02 PM UTC